Arcus Biosciences (RCUS) announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. Leerink Partners and Goldman Sachs & Co. are acting as joint book-running managers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences price target raised to $16 from $14 at Goldman Sachs
- Arcus Biosciences price target raised to $35 from $33 at Wedbush
- Arcus Biosciences price target raised to $56 from $54 at Citi
- Arcus Biosciences price target raised to $28 from $24 at H.C. Wainwright
- Arcus Biosciences Reports Promising Q3 2025 Results